Source:http://linkedlifedata.com/resource/pubmed/id/19329941
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2009-6-4
|
pubmed:abstractText |
Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor. Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy. To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases. Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period. A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied. Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001). All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3. In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate. However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases. Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1530-0285
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
824-32
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:19329941-Adenocarcinoma, Clear Cell,
pubmed-meshheading:19329941-Female,
pubmed-meshheading:19329941-Glypicans,
pubmed-meshheading:19329941-Humans,
pubmed-meshheading:19329941-Immunohistochemistry,
pubmed-meshheading:19329941-Kaplan-Meier Estimate,
pubmed-meshheading:19329941-Middle Aged,
pubmed-meshheading:19329941-Neoplasm Staging,
pubmed-meshheading:19329941-Ovarian Neoplasms,
pubmed-meshheading:19329941-Tumor Markers, Biological
|
pubmed:year |
2009
|
pubmed:articleTitle |
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
|
pubmed:affiliation |
Department of Pathology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|